A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients

被引:98
作者
Pecoits, R
Stenvinkel, P
Marchlewska, A
Heimburger, O
Bárány, P
Hoff, CM
Holmes, CJ
Suliman, M
Lindholm, B
Schalling, M
Nordfors, L
机构
[1] Karolinska Inst, Dept Clin Sci, Div Renal Med & Baxter Novum, S-10401 Stockholm, Sweden
[2] Karolinska Inst, Dept Mol Med, S-10401 Stockholm, Sweden
[3] Baxter Healthcare Corp, Renal Div Sci Affairs, McGaw Pk, IL USA
关键词
end-stage renal disease; oxidative stress; myeloperoxidase; genetic polymorphism;
D O I
10.1046/j.1523-1755.63.s84.32.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Cardiovascular disease (CVD) is the leading cause of mortality in end-stage renal disease (ESRD) patients and there is emerging evidence that genetic factors may contribute to the development of atherosclerosis. Myeloperoxidase (MPO) is an abundant enzyme involved in the production of free radicals. A functional G-->A single nucleotide polymorphism (SNP) has been identified at position -463, where the A allele is associated with lower MPO expression. To analyze the association between this SNP and inflammation, oxidative stress, and CVD, we studied a cohort of 155 ESRD patients (52 +/- 1 years, 62% males, 22% diabetics) shortly before the initiation of dialysis treatment. CVD was defined by medical history criteria; plasma interleukin-6 (IL-6) was used as a marker of inflammation, and plasma pentosidine as an estimation of oxidative protein damage. DNA from leukocytes was used for genotyping, performed by the pyrosequencing reaction. Only five patients (3%) had the genotype AA at the -463 position, whereas 38 (25%) had the GA and 112 (72%) had the GG genotype. No differences were noted in plasma IL-6 levels between the genotype groups, whereas the pentosidine levels were higher in the GG group (28.4 pmol/mg albumin [range, 8.5 to 123 pmol/mg albumin]) compared to the other two groups (21.4 pmol/mg albumin [range, 7.6. to 384 pmol/mg albumin; P < 0.05]). Patients with the GG genotype had a higher prevalence of positive serology for Chlamydia pneumoniae (51%) when compared to the carriers of the A allele (24%) (P < 0.05). The prevalence of CVD was lower in the AA (0%) and GA genotypes (18%), compared to the GG genotype (35%). The GG genotype was still associated with CVD after correction for age, diabetes, smoking, malnutrition, and inflammation. Our findings suggest that the -463 G-->A SNP, which supposedly results in lower MPO activity, is associated with a lower prevalence of CVD in ESRD patients. It could be speculated that this effect is mediated by a decreased oxidative stress due to lower production of free radicals.
引用
收藏
页码:S172 / S176
页数:5
相关论文
共 19 条
[1]   The myeloperoxidase system of human phagocytes generates Nε-(carboxymethyl)lysine on proteins:: a mechanism for producing advances glycation end products at sites of inflammation [J].
Anderson, MM ;
Requena, JR ;
Crowley, JR ;
Thorpe, SR ;
Heinecke, JW .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (01) :103-113
[2]   Widespread coronary inflammation in unstable angina [J].
Buffon, A ;
Biasucci, LM ;
Liuzzo, G ;
D'Onofrio, G ;
Crea, F ;
Maseri, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (01) :5-12
[3]   MYELOPEROXIDASE, A CATALYST FOR LIPOPROTEIN OXIDATION, IS EXPRESSED IN HUMAN ATHEROSCLEROTIC LESIONS [J].
DAUGHERTY, A ;
DUNN, JL ;
RATERI, DL ;
HEINECKE, JW .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (01) :437-444
[4]   Myeloperoxidase, a leukocyte-derived vascular NO oxidase [J].
Eiserich, JP ;
Baldus, S ;
Brennan, ML ;
Ma, WX ;
Zhang, CX ;
Tousson, A ;
Castro, L ;
Lusis, AJ ;
Nauseef, WM ;
White, CR ;
Freeman, BA .
SCIENCE, 2002, 296 (5577) :2391-2394
[5]   3-chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima [J].
Hazen, SL ;
Heinecke, JW .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (09) :2075-2081
[6]   The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia [J].
Himmelfarb, J ;
Stenvinkel, P ;
Ikizler, TA ;
Hakim, RM .
KIDNEY INTERNATIONAL, 2002, 62 (05) :1524-1538
[7]   Myeloperoxidase-catalyzed 3-chlorotyrosine formation in dialysis patients [J].
Himmelfarb, J ;
McMenamin, ME ;
Loseto, G ;
Heinecke, JW .
FREE RADICAL BIOLOGY AND MEDICINE, 2001, 31 (10) :1163-1169
[8]   Growing significance of myeloperoxidase in non-infectious diseases [J].
Hoy, A ;
Leininger-Muller, B ;
Kutter, D ;
Siest, G ;
Visvikis, S .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2002, 40 (01) :2-8
[9]   Consequences of total and subtotal myeloperoxidase deficiency: Risk or benefit? [J].
Kutter, D ;
Devaquet, P ;
Vanderstocken, G ;
Paulus, JM ;
Marchal, V ;
Gothot, A .
ACTA HAEMATOLOGICA, 2000, 104 (01) :10-15
[10]  
London SJ, 1997, CANCER RES, V57, P5001